DIA Stock Overview
Engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for DIA from our risk checks.
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
DiaSorin S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €101.85 |
| 52 Week High | €112.35 |
| 52 Week Low | €82.72 |
| Beta | 0.19 |
| 1 Month Change | -6.47% |
| 3 Month Change | -2.07% |
| 1 Year Change | 4.70% |
| 3 Year Change | -42.83% |
| 5 Year Change | -13.39% |
| Change since IPO | 722.70% |
Recent News & Updates
Is DiaSorin (BIT:DIA) A Risky Investment?
Nov 29
DiaSorin S.p.A. (BIT:DIA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 08Recent updates
Is DiaSorin (BIT:DIA) A Risky Investment?
Nov 29DiaSorin S.p.A. (BIT:DIA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 08DiaSorin S.p.A. (BIT:DIA) Investors Are Less Pessimistic Than Expected
Aug 23DiaSorin S.p.A. (BIT:DIA) Just Released Its Interim Results And Analysts Are Updating Their Estimates
Aug 01We Think DiaSorin (BIT:DIA) Can Stay On Top Of Its Debt
Jul 16DiaSorin's (BIT:DIA) Dividend Will Be Increased To €1.15
Apr 09DiaSorin (BIT:DIA) Is Paying Out A Larger Dividend Than Last Year
Mar 25DiaSorin S.p.A. (BIT:DIA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Mar 20DiaSorin S.p.A.'s (BIT:DIA) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 17Is DiaSorin (BIT:DIA) Using Too Much Debt?
Jan 25Shareholder Returns
| DIA | IT Medical Equipment | IT Market | |
|---|---|---|---|
| 7D | -2.8% | -0.9% | 1.9% |
| 1Y | 4.7% | 18.6% | 13.4% |
Return vs Industry: DIA underperformed the Italian Medical Equipment industry which returned 18.6% over the past year.
Return vs Market: DIA underperformed the Italian Market which returned 13.4% over the past year.
Price Volatility
| DIA volatility | |
|---|---|
| DIA Average Weekly Movement | 3.4% |
| Medical Equipment Industry Average Movement | 5.1% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IT Market | 7.9% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: DIA has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: DIA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 3,186 | Carlo Rosa | diasoringroup.com/en |
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System.
DiaSorin S.p.A. Fundamentals Summary
| DIA fundamental statistics | |
|---|---|
| Market cap | €5.49b |
| Earnings (TTM) | €188.85m |
| Revenue (TTM) | €1.18b |
28.8x
P/E Ratio4.6x
P/S RatioIs DIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIA income statement (TTM) | |
|---|---|
| Revenue | €1.18b |
| Cost of Revenue | €406.02m |
| Gross Profit | €772.19m |
| Other Expenses | €583.34m |
| Earnings | €188.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.54 |
| Gross Margin | 65.54% |
| Net Profit Margin | 16.03% |
| Debt/Equity Ratio | 42.6% |
How did DIA perform over the long term?
See historical performance and comparison